Printer Friendly

AMERICAN JOURNAL OF CARDIOLOGY REPORTS SAFETY OF OMNIPAQUE (IOHEXOL) IN CARDIAC ANGIOGRAPHY

 NEW YORK, Oct. 7 /PRNewswire/ -- Sterling Winthrop Inc. today applauded the findings of a new study that further confirms the safety of its Omnipaque(R) nonionic diagnostic imaging agent. The study, published in the Oct. 1 issue of the American Journal of Cardiology, concludes that Omnipaque (iohexol) diagnostic imaging agent, a nonionic low osmolar monomer, is associated with a lower incidence of adverse events during cardiac angiography when compared with Renografin(R) (sodium meglumine diatrizoate), an ionic high osmolar monomeric imaging agent.
 Cardiac angiography is a procedure used by physicians to detect heart disease and abnormalities.
 Sterling Winthrop's pharmaceuticals unit, Sanofi Winthrop, markets the Omnipaque product in the U.S., Canada, and other markets. Omnipaque is used in cardiac angiography, CT scanning and other radiographic procedures.
 "Among the 1,462 patients in the double-blind, randomized study, mild, moderate and severe reactions occurred significantly less frequently with Omnipaque contrast media. This study clearly demonstrates the added safety of Omnipaque as compared to the ionic agent," said Mary J. Murphy, MD, MPH, Senior Associate Medical Director, Sanofi Winthrop. "More than 80 percent of those patients given Omnipaque imaging agent were free of adverse reactions, compared with 60 percent in the diatrizoate group.
 "For example," continued Dr. Murphy, "patients given Omnipaque experienced half as many episodes of angina, one third as many hypotensive episodes, and one tenth as many episodes of pulmonary edema (fluid in the lungs) compared to the patients given the other imaging agent. This is clearly an advantage for cardiologists as well as patients.
 "Overall, the data indicates that it is approximately four times less likely for a moderately severe cardiac adverse event to occur with Omnipaque. Although not specifically evaluated in this study, the higher incidence of adverse reactions seen with ionic contrast affects patient management and increases procedural costs," said Dr. Murphy.
 "The results of this study confirm the current rationale for the selection of nonionic contrast media in approximately 85 percent of cardiac angiography procedures performed in the U.S. today," concluded Dr. Murphy.
 The study was funded in part by Sanofi Winthrop Pharmaceuticals.
 Omnipaque is marketed in the U.S. by Sanofi Winthrop, the pharmaceuticals marketing alliance between Sterling Winthrop Inc., and Elf Sanofi. Headquartered in New York City, Sterling Winthrop is a worldwide developer, manufacturer and marketer of pharmaceuticals and consumer health products.
 -0- 10/7/93
 /CONTACT: Carol Perlman, 212-907-2724, or Diane Iselin, 212-907-2341, both of Sterling Winthrop Inc./


CO: Sterling Winthrop ST: New York IN: MTC SU:

LG-OS -- NY001 -- 1225 10/07/93 09:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 7, 1993
Words:423
Previous Article:BRADLEES REPORTS SEPTEMBER SALES
Next Article:VALUE LINE INTRODUCES NEW SURVEY TO GUIDE MUTUAL FUND INVESTORS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters